Literature DB >> 26615417

In Vitro Activities of Five Antifungal Drugs Against Opportunistic Agents of Aspergillus Nigri Complex.

Hamid Badali1, Hamed Fakhim2, Fereshteh Zarei3, Mojtaba Nabili2, Afsane Vaezi2, Nafiseh Poorzad2, Somayeh Dolatabadi4,5, Hossein Mirhendi6.   

Abstract

Black aspergilli, particularly Aspergillus niger and A. tubingensis, are the most common etiological agents of otomycosis followed by onychomycosis, pulmonary aspergillosis and aspergilloma. However, so far there is no systematic study on their antifungal susceptibility profiles. A collection of 124 clinical and environmental species of black aspergilli consisted of A. niger, A. tubingensis, A. uvarum. A. acidus and A. sydowii were verified by DNA sequencing of the partial β-tubulin gene. MICs of amphotericin B, itraconazole, voriconazole, posaconazole, and MECs of caspofungin were performed based on CLSI M38-A2. Posaconazole and caspofungin had the lowest MIC range (0.016-0.125 µg/ml and 0.008-0.031 µg/ml, respectively), followed by amphotericin B (0.25-4 µg/ml), voriconazole (0.125-16 µg/ml) and itraconazole (0.25 to >16) in an increasing order. Some strains of A. niger showed high MIC value for itraconazole and voriconazole (>16 µg/ml), in contrast only environmental isolates of A. tubingensis had high itraconazole MICs (>16 µg/ml). These results confirm that posaconazole and caspofungin are potential drugs for treatment of aspergillosis due to opportunistic agents of Aspergillus Nigri complex. However, in vivo efficacy remains to be determined.

Entities:  

Keywords:  Aspergillus Nigri complex; In vitro susceptibility; Partial β-tubulin (BTU)

Mesh:

Substances:

Year:  2015        PMID: 26615417     DOI: 10.1007/s11046-015-9968-0

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  21 in total

1.  Black Aspergillus species isolated from clinical and environmental samples in Iran.

Authors:  Fereshteh Zarei; Hossein Mirhendi; Marjan Motamedi; Bahram Ahmadi; Sadegh Nouripour-Sisakht; Hossein Zarrinfar; Nilufar Jalalizand; Jamal Hashemi
Journal:  J Med Microbiol       Date:  2015-09-18       Impact factor: 2.472

2.  Phylogenetic analysis of Aspergillus species using DNA sequences from four loci.

Authors:  Stephen W Peterson
Journal:  Mycologia       Date:  2008 Mar-Apr       Impact factor: 2.696

3.  Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET).

Authors:  Peter G Pappas; Barbara D Alexander; David R Andes; Susan Hadley; Carol A Kauffman; Alison Freifeld; Elias J Anaissie; Lisa M Brumble; Loreen Herwaldt; James Ito; Dimitrios P Kontoyiannis; G Marshall Lyon; Kieren A Marr; Vicki A Morrison; Benjamin J Park; Thomas F Patterson; Trish M Perl; Robert A Oster; Mindy G Schuster; Randall Walker; Thomas J Walsh; Kathleen A Wannemuehler; Tom M Chiller
Journal:  Clin Infect Dis       Date:  2010-04-15       Impact factor: 9.079

4.  Genetic re-identification and antifungal susceptibility testing of Aspergillus section Nigri strains of the BCCM/IHEM collection.

Authors:  M Hendrickx; H Beguin; M Detandt
Journal:  Mycoses       Date:  2011-09-20       Impact factor: 4.377

5.  Molecular identification and antifungal susceptibilities of black Aspergillus isolates from otomycosis cases in Hungary.

Authors:  Gyöngyi Szigeti; Sándor Kocsubé; Ilona Dóczi; László Bereczki; Csaba Vágvölgyi; János Varga
Journal:  Mycopathologia       Date:  2012-02-23       Impact factor: 2.574

Review 6.  Multi-resistant aspergillosis due to cryptic species.

Authors:  Susan Julie Howard
Journal:  Mycopathologia       Date:  2014-06-27       Impact factor: 2.574

7.  Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.

Authors:  Laura Alcazar-Fuoli; Emilia Mellado; Ana Alastruey-Izquierdo; Manuel Cuenca-Estrella; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191

8.  In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.

Authors:  Ayse Demet Kaya; Nuri Kiraz
Journal:  Mycoses       Date:  2007-11       Impact factor: 4.377

9.  Environmental study of azole-resistant Aspergillus fumigatus with TR34/L98H mutations in the cyp51A gene in Iran.

Authors:  Hamid Badali; Afsane Vaezi; Iman Haghani; Seyed A Yazdanparast; Mohammad T Hedayati; Bita Mousavi; Saham Ansari; Ferry Hagen; Jacques F Meis; Anuradha Chowdhary
Journal:  Mycoses       Date:  2013-05-14       Impact factor: 4.377

Review 10.  Emergence of azole-resistant aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health.

Authors:  Anuradha Chowdhary; Shallu Kathuria; Jianping Xu; Jacques F Meis
Journal:  PLoS Pathog       Date:  2013-10-24       Impact factor: 6.823

View more
  13 in total

1.  Species Distribution and In Vitro Azole Susceptibility of Aspergillus Section Nigri Isolates from Clinical and Environmental Settings.

Authors:  Roberta Iatta; Federica Nuccio; Davide Immediato; Adriana Mosca; Carmela De Carlo; Giuseppe Miragliotta; Antonio Parisi; Giuseppe Crescenzo; Domenico Otranto; Claudia Cafarchia
Journal:  J Clin Microbiol       Date:  2016-07-13       Impact factor: 5.948

2.  Molecular Identification and Antifungal Susceptibility of Yeasts and Molds Isolated from Patients with Otomycosis.

Authors:  Keyvan Kiakojuri; Saeid Mahdavi Omran; Somayeh Roodgari; Mojtaba Taghizadeh Armaki; Mohammad Taghi Hedayati; Tahereh Shokohi; Iman Haghani; Javad Javidnia; Firoozeh Kermani; Hamid Badali; Mahdi Abastabar
Journal:  Mycopathologia       Date:  2021-03-15       Impact factor: 2.574

3.  Species Identification and In Vitro Antifungal Susceptibility of Aspergillus terreus Species Complex Clinical Isolates from a French Multicenter Study.

Authors:  E Dannaoui; F Botterel; S Imbert; A C Normand; S Ranque; J M Costa; J Guitard; I Accoceberry; C Bonnal; A Fekkar; N Bourgeois; S Houzé; C Hennequin; R Piarroux
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

4.  New Insights into the Cyp51 Contribution to Azole Resistance in Aspergillus Section Nigri.

Authors:  Alba Pérez-Cantero; Loida López-Fernández; Josep Guarro; Javier Capilla
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

5.  Antifungal Activity of a Novel Triazole, Efinaconazole and Nine Comparators against 354 Molecularly Identified Aspergillus Isolates.

Authors:  Zahra Taheri Rizi; Mahdi Abastabar; Hamed Fakhim; Macit Ilkit; Fatemeh Ahangarkani; Javad Javidnia; Iman Haghani; Jacques F Meis; Hamid Badali
Journal:  Mycopathologia       Date:  2020-02-28       Impact factor: 2.574

Review 6.  Coinfection of Pulmonary Hydatid Cyst and Aspergilloma: Case Report and Systematic Review.

Authors:  Masoud Aliyali; Hamid Badali; Tahereh Shokohi; Maryam Moazeni; Anahita Nosrati; Gholamali Godazandeh; Somayeh Dolatabadi; Mojtaba Nabili
Journal:  Mycopathologia       Date:  2015-12-14       Impact factor: 2.574

7.  Low In Vitro Antifungal Activity of Tavaborole against Yeasts and Molds from Onychomycosis.

Authors:  Mahdi Abastabar; Iman Haghani; Tahereh Shokohi; Mohammad Taghi Hedayati; Seyed Reza Aghili; Ali Jedi; Sulmaz Dadashi; Shafigheh Shabanzadeh; Tahereh Hosseini; Narges Aslani; Jacques F Meis; Hamid Badali
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

8.  Treatment of Otomycosis in Ears with Tympanic Membrane Perforation is Easier with Paper Patch.

Authors:  Kemal Görür; Onur İsmi; Cengiz Özcan; Yusuf Vayısoğlu
Journal:  Turk Arch Otorhinolaryngol       Date:  2019-12-01

Review 9.  Emergence of Triazole Resistance in Aspergillus spp. in Latin America.

Authors:  Daiana Macedo; Florencia Leonardelli; Soledad Gamarra; Guillermo Garcia-Effron
Journal:  Curr Fungal Infect Rep       Date:  2021-05-19

Review 10.  Epidemiological and Genomic Landscape of Azole Resistance Mechanisms in Aspergillus Fungi.

Authors:  Daisuke Hagiwara; Akira Watanabe; Katsuhiko Kamei; Gustavo H Goldman
Journal:  Front Microbiol       Date:  2016-09-21       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.